论文部分内容阅读
罗格列酮(ＲＳＧ)属噻唑烷类药物,单独用于治疗2型糖尿病剂量为8ｍｇ/ｄ时即有效。587名2型糖尿病病人随机、双盲研究,观察ＲＳＧ4ｍｇ/ｄ和8ｍｇ/ｄ两组与最适量优降糖(ＧＬＢ)组治疗12个月的药效比较。受试病人或单纯饮食治疗或随机化前口服6周药物治疗。结果见表。从研究结?
Rosiglitazone (RSG) is a thiazolidine that is effective alone when used to treat type 2 diabetes at doses of 8 mg / day. 587 patients with type 2 diabetes were randomized, double-blind study to observe the RSG 4mg / d and 8mg / d two groups compared with the optimal amount of glyburide (GLB) group for 12 months of efficacy comparison. Subjects were either treated on diet alone or orally for 6 weeks prior to randomization. The results shown in the table. From the study conclusion?